Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can Blood-Based injections realign the jaw joint?

NCT ID NCT07798258

Disease control Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This trial compares two injection treatments for a common jaw joint problem where the disc slips out of place but returns, causing pain and clicking. One treatment uses a concentrate from the patient's own blood, called platelet-rich fibrin, while the other uses a sugar solution. Researchers will measure whether either injection improves the disc's position on MRI, reduces pain, and improves mouth opening. The study includes adult women with this condition, and each participant receives three injections over four weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Injectable platelet-rich fibrin (I-PRF) compared with 25% dextrose prolotherapy
What this could lead to
If I-PRF works, it could offer a more effective, minimally invasive treatment for jaw joint pain and clicking, potentially avoiding surgery.
What could go wrong
This is a small, early-stage trial with only 24 participants, so results may not apply broadly. Injections carry risks like pain, swelling, or infection, and the treatment may not improve disc position or symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 24 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants must meet all of the following criteria: Age ≥18 years. Female patients. Patients with anterior disc displacement with reduction. Anterior disc displacement with reduction assessed using preoperative MRI in open- and closed-mouth positions. Patients who are willing and fully capable of complying with the study protocol. Exclusion Criteria: * Participants will be excluded if they have: Bleeding disorders or are receiving anticoagulant medications. Pregnancy. Bony pathology of the temporomandibular joint. Temporomandibular disorder patients or patients with anterior disc displacement without reduction. Any temporomandibular joint infection. Mental instabilities or psychiatric conditions. Previous invasive or surgical procedures of the temporomandibular joint. Inability to attend follow-up during the entire follow-up period. Refusal to sign the written informed consent. Dystonia.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TMD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

temporomandibular joint disorder transient myeloproliferative syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TMD

Contacts and locations

Locations

  • Faculty of Dentistry, Cairo University

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.